ND-L02-s0201

Status
Phase 2
Condition
Idiopathic Pulmonary Fibrosis
Intervention Type
Intravenous (IV) Injection
Funder Type
Industry

Drug Details

ND-L02-s0201 is an oligonucleotide drug using HSP47 (Heat Shock Protein 47) siRNA, which moderates collagen synthesis and secretion that causes fibrosis.

Study Purpose

This phase 2 clinical study will be a randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, biological activity, and pharmacokinetics (PK) of ND-L02-s0201 for Injection in subjects with IPF.

Find a Clinical Trial  
 
footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >